1-13 of 13
Ulrike Weyer-Czernilofsky
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB003: BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Andreas Gollner, Patrizia Sini, Dorothea Rudolph, Harald Weinstabl, Juergen Ramharter, Ulrike Weyer-Czernilofsky, Bojana Golubovic, Rolf Grempler, Alejandro Pérez Pitarch, Reinhard Sailer, Darryl B. McConnell, Norbert Kraut
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB003.
https://doi.org/10.1158/1538-7445.AM2023-LB003
Published: 14 April 2023
View article titled, Abstract LB003: BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules
Journal Articles

Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Guillaume Rieunier, Xiaoning Wu, Letitia E. Harris, Jack V. Mills, Ashwin Nandakumar, Laura Colling, Elena Seraia, Stephanie B. Hatch, Daniel V. Ebner, Lisa K. Folkes, Ulrike Weyer-Czernilofsky, Thomas Bogenrieder, Anderson J. Ryan, Valentine M. Macaulay
Journal: Cancer Research
Cancer Res (2021) 81 (8): 2128–2141.
https://doi.org/10.1158/0008-5472.CAN-20-2860
Published: 15 April 2021
View article titled, Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction
Open the PDF for Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction in another window
Includes: Supplementary data
Journal Articles

Abstract 3055: Xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, shows efficacy in a human breast cancer model of bone metastasis

Ulrike Weyer-Czernilofsky, Izabela Krecioch, Stephan Handschuh, Martin Glösmann, Mario Kuttke, Robin Jacob, Anna C. Obenauf
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3055.
https://doi.org/10.1158/1538-7445.AM2020-3055
Published: 15 August 2020
View article titled, Abstract 3055: Xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, shows efficacy in a human breast cancer model of bone metastasis
Journal Articles

Abstract 4190: A promising blood-brain-barrier penetrant MDM2-p53 antagonist, BI-MDM2, increases survival in orthotopic, glioblastoma patient-derived xenograft models

Ann C. Mladek Tuma, Shiv Gupta, Surabhi Talele, Afroz Shareef Mohammad, Katrina K. Bakken, Helen He, Zeng Hu, Margaret A. Connors, Danielle M. Burgenske, Brett L. Carlson, William F. Elmquist, Ulrike Weyer-Czernilofsky, Jann N. Sarkaria
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4190.
https://doi.org/10.1158/1538-7445.AM2020-4190
Published: 15 August 2020
View article titled, Abstract 4190: A promising blood-brain-barrier penetrant MDM2-p53 antagonist, BI-MDM2, increases survival in orthotopic, glioblastoma patient-derived xenograft models
Journal Articles

Abstract 3197: BI-907828, a novel and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer

Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Markus Reschke, Martina Sykora, Jörg Rinnenthal, Sophia Blake, Gabriela Gremel, Andreas Wernitznig, Andreas Gollner, Norbert Kraut, Jürgen Moll
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3197.
https://doi.org/10.1158/1538-7445.AM2019-3197
Published: 01 July 2019
View article titled, Abstract 3197: BI-907828, a novel and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer
Journal Articles

Abstract 1852: Combination of the CDK4/6 inhibitor abemaciclib with xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, results in synergistic antineoplastic effects in human breast cancer cell lines

Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Susanne Schmittner, Xueqian Gong, Sean Buchanan, Richard P. Beckmann, Carlos Marugan, Raquel Torres, Karsten Boehnke, Maria Jose Lallena, Flavio Solca, Norbert Kraut, Thomas Bogenrieder
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1852.
https://doi.org/10.1158/1538-7445.AM2018-1852
Published: 01 July 2018
View article titled, Abstract 1852: Combination of the CDK4/6 inhibitor abemaciclib with xentuzumab, a humanized IGF-1 and IGF-2 ligand co-neutralizing monoclonal antibody, results in synergistic antineoplastic effects in human breast cancer cell lines
Journal Articles

Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules

Dorothea Rudolph, Andreas Gollner, Sophia Blake, Jörg Rinnenthal, Andreas Wernitznig, Ulrike Weyer-Czernilofsky, Christian Haslinger, Pilar Garin-Chesa, Jens Quant, Darryl B. McConnell, Jürgen Moll, Kraut Norbert
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4868.
https://doi.org/10.1158/1538-7445.AM2018-4868
Published: 01 July 2018
View article titled, Abstract 4868: BI 907828: A novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules
Journal Articles

Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer

Dorothea Rudolph, Markus Reschke, Sophia Blake, Jörg Rinnenthal, Andreas Wernitznig, Ulrike Weyer-Czernilofsky, Andreas Gollner, Christian Haslinger, Pilar Garin-Chesa, Jens Quant, Darryl B. McConnell, Kraut Norbert, Jürgen Moll
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4866.
https://doi.org/10.1158/1538-7445.AM2018-4866
Published: 01 July 2018
View article titled, Abstract 4866: BI 907828: A novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer
Journal Articles

Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic

Joerg Rinnenthal, Dorothea Rudolph, Sophia Blake, Andreas Gollner, Andreas Wernitznig, Ulrike Weyer-Czernilofsky, Christian Haslinger, Pilar Garin-Chesa, Jürgen Moll, Norbert Kraut, Darryl McConnell, Jens Quant
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4865.
https://doi.org/10.1158/1538-7445.AM2018-4865
Published: 01 July 2018
View article titled, Abstract 4865: BI 907828: A highly potent MDM2 inhibitor with low human dose estimation, designed for high-dose intermittent schedules in the clinic
Journal Articles

Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage

Tamara Aleksic, Nicki Gray, Xiaoning Wu, Guillaume Rieunier, Eliot Osher, Jack Mills, Clare Verrill, Richard J. Bryant, Cheng Han, Kathryn Hutchinson, Adam G. Lambert, Rajeev Kumar, Freddie C. Hamdy, Ulrike Weyer-Czernilofsky, Michael P. Sanderson, Thomas Bogenrieder, Stephen Taylor, Valentine M. Macaulay
Journal: Cancer Research
Cancer Res (2018) 78 (13): 3497–3509.
https://doi.org/10.1158/0008-5472.CAN-17-3498
Published: 01 July 2018
View article titled, Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage
Open the PDF for Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage in another window
Includes: Supplementary data
Journal Articles

Abstract 20: Xentuzumab, a humanized IGF-1 and IGF-2 ligand neutralizing antibody, improves the antitumor efficacy of enzalutamide in preclinical models of prostate cancer

Ulrike Weyer-Czernilofsky, Marco H. Hofmann, Paul J. Adam, Flavio Solca, Katrin Friedbichler, Norbert Kraut, Eva Corey, Thomas Bogenrieder
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 20.
https://doi.org/10.1158/1538-7445.AM2017-20
Published: 01 July 2017
View article titled, Abstract 20: Xentuzumab, a humanized IGF-1 and IGF-2 ligand neutralizing antibody, improves the antitumor efficacy of enzalutamide in preclinical models of prostate cancer
Journal Articles

Abstract 1194: Neutralization of IGF-I and -II ligands with the fully humanized bispecific monoclonal antibody xentuzumab inhibits AR-V7-induced enzalutamide resistance in castration-resistant prostate cancer

Gang Liu, Holly M. Nguyen, Kristine van Maltzan, Shihua Sun, Cynthia Sprenger, Ulrike Weyer-Czernilofsky, Eva Corey, Stephen R. Plymate
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1194.
https://doi.org/10.1158/1538-7445.AM2017-1194
Published: 01 July 2017
View article titled, Abstract 1194: Neutralization of IGF-I and -II ligands with the fully humanized bispecific monoclonal antibody xentuzumab inhibits AR-V7-induced enzalutamide resistance in castration-resistant prostate cancer
Journal Articles

Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors

Lucy Ireland, Almudena Santos, Muhammad S. Ahmed, Carolyn Rainer, Sebastian R. Nielsen, Valeria Quaranta, Ulrike Weyer-Czernilofsky, Danielle D. Engle, Pedro A. Perez-Mancera, Sarah E. Coupland, Azzam Taktak, Thomas Bogenrieder, David A. Tuveson, Fiona Campbell, Michael C. Schmid, Ainhoa Mielgo
Journal: Cancer Research
Series: Author Choice
Cancer Res (2016) 76 (23): 6851–6863.
https://doi.org/10.1158/0008-5472.CAN-16-1201
Published: 30 November 2016
View article titled, Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Open the PDF for Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors in another window
Includes: Supplementary data